Skip to main content

Table 3 Active injury score, regeneration score, and chronicity score in OSOM of different experimental groups (n = 20 and n = 5 for days subgroups, mean ± SD)

From: Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague-Dawley rats

  Group I Group II Group III Group IV Group V Group VI
negative control cisplatin ‘CDDP’-treated cisplatin + rBMSCs-treated cisplatin + hADSCs-treated (n = 20) cisplatin + hAFSCs-treated cisplatin + DMEM culture media-treated
Active injury
 Day 4 0.0 (0.0–0.0) 7.0 (7.0–7.0)a 3.0 (2.0–3.0)ab 3.0 (2.0–3.0)ab 3.0 (2.0–3.0)ab 6.0 (6.0–7.0)abcde
 Day 7 0.0 (0.0–0.0) 6.0 (6.0–6.0)a 3.0 (3.0–3.0)ab 3.0 (2.0–3.0)ab 3.0 (2.0–3.0)ab 6.0 (6.0–6.0)abcde
 Day 11 0.0 (0.0–0.0) 4.0 (4.0–4.0)a 1.0 (1.0–1.0)ab 1.0 (1.0–1.0)ab 1.0 (1.0–1.0)ab 6.0 (5.0–6.0)abcde
 Day 30 0.0 (0.0–0.0) 4.0 (4.0–4.0)a 1.0 (0.0–1.0)b 1.0 (1.0–1.0)b 1.0 (1.0–1.0)ab 3.0 (3.0–3.0)abcde
Regeneration
 Day 4 0.0 (0.0–0.0) 0.0 (0.0–0.0) 4.0 (4.0–5.0)ab 4.0 (4.0–5.0)ab 4.0 (3.0–5.0)ab 0.0 (0.0–0.0)cde
 Day 7 0.0 (0.0–0.0) 0.0 (0.0–0.0) 6.0 (5.0–6.0)ab 6.0 (6.0–6.0)ab 7.0 (6.0–7.0)abc 0.0 (0.0–0.0)cde
 Day 11 0.0 (0.0–0.0) 1.0 (1.0–2.0)a 8.0 (7.0–8.0)ab 8.0 (7.0–9.0)ab 8.0 (8.0–8.0)ab 1.0 (1.0–2.0)acde
 Day 30 0.0 (0.0–0.0) 3.0 (3.0–3.0)a 9.0 (8.0–9.0)ab 8.0 (7.0–9.0)ab 8.0 (7.0–9.0)ab 3.0 (3.0–3.0)acde
Chronicity
 Day 4 0.0 (0.0–0.0) 3.0 (3.0–3.0)a 2.0 (1.0–2.0)ab 2.0 (1.0–2.0)ab 2.0 (2.0–2.0)ab 3.0 (3.0–3.0)acde
 Day 7 0.0 (0.0–0.0) 4.0 (4.0–4.0)a 2.0 (2.0–3.0)ab 2.0 (2.0–2.0)ab 2.0 (2.0–2.0)ab 4.0 (4.0–5.0)acde
 Day 11 0.0 (0.0–0.0) 5.0 (5.0–5.0)a 2.0 (2.0–2.0)ab 2.0 (2.0–2.0)ab 2.0 (2.0–2.0)ab 5.0 (5.0–5.0)acde
 Day 30 0.0 (0.0–0.0) 3.0 (3.0–4.0)a 2.0 (2.0–2.0)ab 2.0 (2.0–2.0)ab 2.0 (2.0–2.0)ab 3.0 (3.0–3.0)acde
  1. Values are expressed as mean ± SD. A significant difference (P < 0.05) between different groups was done by Kruskal-Wallis test
  2. OSOM outer strip of outer medulla, rBMSCs rat bone marrow stem cells, hADSCs human adipose tissue-derived stem cells, hAFSCs human amniotic fluid-derived stem cells, DMEM Dulbecco’s modified Eagle’s medium
  3. aSignificant difference vs. negative control group bSignificant difference vs. cisplatin-treated group cSignificant difference vs. cisplatin + rBMSCs-treated group dSignificant difference vs. cisplatin + hADSCs-treated group eSignificant difference vs. cisplatin + hAFSCs-treated group